SCHEMBL20799360

SCHEMBL20799360

CNc1cc(C)nc(NC(=N)Nc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
EHMT2 Q96KQ7 1/20 0.41
EHMT1 Q9H9B1 1/20 0.41
MAPT P10636 6/20 0.39
ALDH1A1 P00352 4/20 0.39
GBA1 P04062 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
EPHX1 P07099 1/20 0.39
EPHX2 P34913 1/20 0.39
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTT P42858 2/20 0.38
CYP3A4 P08684 1/20 0.38
APEX1 P27695 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17985492 0.85 KMT2A (0.49) NPC1RAB9AMAPTALDH1A1GBA1
SCHEMBL4103203 0.84 NPC1 (0.43) NPC1RAB9AMAPTALDH1A1GBA1
SCHEMBL17985484 0.84 ADRA2A (0.47) NPC1RAB9AMAPTALDH1A1GBA1
SCHEMBL18019581 0.83 NPC1 (0.42) NPC1RAB9AMAPTALDH1A1GBA1
SCHEMBL17985674 0.83 STK17A (0.39) NPC1RAB9AMAPTALDH1A1LMNA
SCHEMBL17985700 0.82 LMNA (0.48) NPC1RAB9AMAPTLMNAMEN1
SCHEMBL17985529 0.81 MEN1 (0.45) NPC1RAB9AMAPTALDH1A1LMNA
SCHEMBL17985701 0.80 ADORA2A (0.42) NPC1RAB9AEHMT2EHMT1MAPT
SCHEMBL17985676 0.80 ADORA2A (0.42) NPC1RAB9AMAPTALDH1A1GBA1
SCHEMBL17985643 0.80 DNM2 (0.46) NPC1RAB9AMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227333-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2019-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227333-B2 Inhibition of OLIG2 activity GLI2, ING2, GMFG NPC1 4224/4885RAB9A 3638/4885EHMT2 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.